14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
LYRA vs WST: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, West Pharmaceutical Services, Inc. (WST) is the stronger overall head-to-head candidate over Lyra Therapeutics, Inc. (LYRA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LYRA carries a Unified Composite Score of 52.2/100 (HOLD) at $0.49 (N/M Forward P/E, -25032.0% operating margin), whereas WST carries 39.8/100 (SELL) at $413.28 (40.2x Forward P/E, 22.9% operating margin).
Composite vs. Pillar Nuance: While LYRA currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. WST 39.8/100 SELL), WST captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (22.9% vs. -25032.0% operating margin) and revenue trajectory (+8.7% vs. -87.2% YoY).
Technical & Structure Timing Caution: LYRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5); meanwhile WST trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 63.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $2.3M market capitalization and -25032.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
WST Moat ProfileScale & Operating Efficiency Moat
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $29.0B market capitalization and 22.9% operating margin.
OpEx & R&D Reinvestment14.7% of Rev ($499M)
90D Engineering Disclosures0 Published
Investor FAQ LYRA vs WST Key Questions & Quantitative Answers
As of Nov 17, 2026, West Pharmaceutical Services, Inc. (WST) is the stronger overall head-to-head candidate over Lyra Therapeutics, Inc. (LYRA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LYRA carries a Unified Composite Score of 52.2/100 (HOLD) at $0.49 (N/M Forward P/E, -25032.0% operating margin), whereas WST carries 39.8/100 (SELL) at $413.28 (40.2x Forward P/E, 22.9% operating margin). Composite vs. Pillar Nuance: While LYRA currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. WST 39.8/100 SELL), WST captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (22.9% vs. -25032.0% operating margin) and revenue trajectory (+8.7% vs. -87.2% YoY). Technical & Structure Timing Caution: LYRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5); meanwhile WST trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 63.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
WST leads the Growth & Scale pillar: LYRA posts -87.2% YoY revenue growth and +0.0% YoY earnings growth on $600,000 TTM revenue (N/A gross margin, -25032.0% operating margin), compared with WST at +8.7% YoY revenue growth and +57.3% YoY earnings growth on $3.40B TTM revenue (37.6% gross margin, 22.9% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), LYRA cumulative revenue shifted N/A while WST shifted +78.5%. In operating R&D and SG&A reinvestment, LYRA deploys N/A (0 90-day corporate R&D disclosures) versus 14.7% of Rev ($499M) (0 disclosures) for WST.
WST screens cheaper on headline valuation multiples. LYRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (unreported EBITDA margin), whereas WST trades at 40.2x Forward P/E, 46.7x Trailing P/E, 3.03x PEG, and 8.5x EV/Revenue (13.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LYRA (-404.5% ROE) versus WST (21.2% ROE) capital efficiency.
In options market volatility and institutional positioning, LYRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.33β · 248% Vol realized risk). By comparison, WST carries 26.0% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.46β · 24% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.